Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination.
CVID
azoximer bromide
influenza
quadrivalent adjuvanted influenza vaccines
toll-like receptors
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
14 10 2023
14 10 2023
Historique:
received:
14
09
2023
revised:
06
10
2023
accepted:
11
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
for the first time, the effect of one and two doses of adjuvanted influenza vaccines on toll-like receptors (TLRs) in patients with common variable immunodeficiency (CVID) was studied and compared (primary vaccination with one vs. two doses, primary vs. repeated vaccination). Six patients received one dose of quadrivalent adjuvanted influenza vaccine during the 2018-2019 and 2019-2020 influenza seasons, and nine patients with CVID received two doses of trivalent inactivated influenza vaccine during 2019-2020. Expression of TLRs was measured by flow cytometry. The expression of toll-like receptors in patients with CVID was noted both with repeated (annual) administration of the influenza vaccine and in most cases was accompanied by an increase in the proportion of granulocytes (TLR3 and TLR9), lymphocytes (TLR3 and TLR8), and monocytes (TLR3 and TLR9). When carried out for the first time as a simultaneous vaccination with two doses it was accompanied by an increase in the proportion of granulocytes, lymphocytes expressing TLR9, and on monocytes-TLR3 and TLR9. in CVID patients, the use of adjuvanted vaccines is promising, and research on the influence of the innate immunity and more effective regimens should be continued.
Sections du résumé
BACKGROUND
for the first time, the effect of one and two doses of adjuvanted influenza vaccines on toll-like receptors (TLRs) in patients with common variable immunodeficiency (CVID) was studied and compared (primary vaccination with one vs. two doses, primary vs. repeated vaccination).
MATERIALS AND METHODS
Six patients received one dose of quadrivalent adjuvanted influenza vaccine during the 2018-2019 and 2019-2020 influenza seasons, and nine patients with CVID received two doses of trivalent inactivated influenza vaccine during 2019-2020. Expression of TLRs was measured by flow cytometry.
RESULTS
The expression of toll-like receptors in patients with CVID was noted both with repeated (annual) administration of the influenza vaccine and in most cases was accompanied by an increase in the proportion of granulocytes (TLR3 and TLR9), lymphocytes (TLR3 and TLR8), and monocytes (TLR3 and TLR9). When carried out for the first time as a simultaneous vaccination with two doses it was accompanied by an increase in the proportion of granulocytes, lymphocytes expressing TLR9, and on monocytes-TLR3 and TLR9.
CONCLUSION
in CVID patients, the use of adjuvanted vaccines is promising, and research on the influence of the innate immunity and more effective regimens should be continued.
Identifiants
pubmed: 37896869
pii: v15102091
doi: 10.3390/v15102091
pmc: PMC10611272
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Toll-Like Receptor 3
0
Toll-Like Receptor 9
0
Toll-Like Receptors
0
Adjuvants, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:39-46
pubmed: 26256294
J Leukoc Biol. 2004 Mar;75(3):422-7
pubmed: 14726494
Front Immunol. 2019 Nov 28;10:2693
pubmed: 31849934
Semin Immunol. 2009 Aug;21(4):185-93
pubmed: 19502082
F1000Res. 2022 Mar 2;11:259
pubmed: 36176546
Ann N Y Acad Sci. 2010 Jan;1183:58-68
pubmed: 20146708
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89
pubmed: 21643519
Expert Rev Vaccines. 2013 Sep;12(9):1085-94
pubmed: 24024871
Nature. 2005 Nov 17;438(7066):364-8
pubmed: 16292312
J Clin Immunol. 2022 Oct;42(7):1473-1507
pubmed: 35748970
BMC Infect Dis. 2017 Apr 26;17(1):308
pubmed: 28441935
Oncoimmunology. 2012 Aug 1;1(5):581-592
pubmed: 22934250
Nat Rev Immunol. 2007 Mar;7(3):179-90
pubmed: 17318230
Eur J Public Health. 2019 Oct 1;29(5):900-905
pubmed: 30929026
Cell Tissue Res. 2011 Jan;343(1):131-40
pubmed: 20824286
Hum Vaccin Immunother. 2012 Jan;8(1):81-8
pubmed: 22252006
J Clin Immunol. 2010 May;30(3):435-41
pubmed: 20177958
Hum Vaccin Immunother. 2019;15(1):113-120
pubmed: 30095325
Med Hypotheses. 2020 Apr 22;140:109752
pubmed: 32361099
Blood. 2003 Aug 1;102(3):956-63
pubmed: 12689944
Wkly Epidemiol Rec. 2018 Mar 23;93(12):133-41
pubmed: 29569429
Immunol Rev. 2006 Jun;211:303-9
pubmed: 16824137
BMC Infect Dis. 2014 Jul 03;14:365
pubmed: 24993051
J Immunol. 2007 Feb 15;178(4):2182-91
pubmed: 17277123
Nat Rev Dis Primers. 2018 Jun 28;4(1):3
pubmed: 29955068
Eur J Immunol. 2006 Apr;36(4):810-6
pubmed: 16541472
Science. 2002 Dec 13;298(5601):2199-202
pubmed: 12481138
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
J Stat Softw. 2016;75:
pubmed: 32655332
Behav Res Methods. 2017 Aug;49(4):1494-1502
pubmed: 27620283
J Allergy Clin Immunol. 2009 Aug;124(2):349-56, 356.e1-3
pubmed: 19592080
J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1066-1075
pubmed: 27836056
Immunotherapy. 2017 Sep;9(12):1035-1050
pubmed: 28871852
Clin Infect Dis. 2014 Feb;58(3):e44-100
pubmed: 24311479
Physiol Genomics. 2007 Sep 19;31(1):114-25
pubmed: 17550995
Immunotherapy. 2018 Feb;10(2):131-137
pubmed: 29260620
Clin Exp Immunol. 2017 Jun;188(3):326-332
pubmed: 28236292
J Immunol. 2006 Feb 1;176(3):1978-87
pubmed: 16424230
Vaccine. 2016 Jul 29;34(35):4092-4102
pubmed: 27381642
Nature. 2005 Feb 24;433(7028):887-92
pubmed: 15711573
Blood. 2003 Jun 1;101(11):4500-4
pubmed: 12560217
Immunotherapy. 2015;7(12):1273-92
pubmed: 26289364
Immunity. 2007 Aug;27(2):240-52
pubmed: 17723216
Am J Med. 1976 Aug;61(2):221-37
pubmed: 782241
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Autoimmun. 2011 Feb;36(1):25-32
pubmed: 21075598
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12
pubmed: 26256290
Semin Immunol. 1998 Oct;10(5):349-50
pubmed: 9799708
J Allergy Clin Immunol. 2018 Dec;142(6):1922-1931.e2
pubmed: 29678747
Zh Mikrobiol Epidemiol Immunobiol. 2016 Sep;(5):23-28
pubmed: 30695345
N Engl J Med. 2000 Aug 3;343(5):338-44
pubmed: 10922424